(Q32156246)

6 July 2017

1 reference

title

Drug resistance among malaria and other parasites (English)

1 reference

6 July 2017

0 references

L M Barat

1

1 reference

6 July 2017

P B Bloland

series ordinal

2

1 reference

6 July 2017

publication date

1 December 1997

1 reference

Infectious Disease Clinics of North America

6 July 2017

published in

1 reference

6 July 2017

volume

11

1 reference

6 July 2017

issue

4

1 reference

6 July 2017

page(s)

969-987

1 reference

Short-term in vitro culture of Plasmodium vivax and P. ovale for drug-susceptibility testing.

6 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

The epidemiology of drug-resistant malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Chloroquine-resistant Plasmodium falciparum from East Africa: cultivation and drug sensitivity of the Tanzanian I/CDC strain from an American tourist

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Primaquine resistance in Plasmodium vivax

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Sulfadoxine-pyrimethamine for the treatment of acute malaria in children of Papua New Guinea. II. Plasmodium vivax

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Treatment of vivax malaria with sulfadoxine-pyrimethamine and with pyrimethamine alone

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Vivax malaria resistant to chloroquine: case reports from Bombay

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Metronidazole and drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Long-term malaria prophylaxis with weekly mefloquine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Treatment of primaquine-resistant Plasmodium vivax malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Development of resistance to chloroquine by Plasmodium vivax in Myanmar

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Mefloquine resistance in Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Vivax malaria resistant to treatment and prophylaxis with chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Mefloquine-resistant falciparum malaria on the Thai-Burmese border

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Cardiac effects of antimalarial treatment with halofantrine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Efficacy of sulphadoxine/pyrimethamine for Plasmodium falciparum malaria in Malawian children under five years of age.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Systematic review of amodiaquine treatment in uncomplicated malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Did medicated salt hasten the spread of chloroquine resistance in Plasmodium falciparum?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Pyrimethamine and Proguanil Resistance-Conferring Mutations in Plasmodium falciparum Dihydrofolate Reductase: Polymerase Chain Reaction Methods for Surveillance in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Atovaquone plus proguanil is an effective treatment for Plasmodium ovale and P. malariae malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Drug sensitivity of plasmodium falciparum. An in-vitro microtechnique

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Plasmodium vivax resistance to chloroquine?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Chloroquine-resistant Plasmodium vivax from Indonesia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Ivermectin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Drug resistance and Giardia.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Current views on the mechanisms of resistance to quinoline-containing drugs inPlasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Epidemiology of drug resistance in malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

Sensitivity of Plasmodium falciparum in vivo to chloroquine and pyrimethamine-sulfadoxine in Rwandan patients in a refugee camp in Zaire

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970400-1

7 January 2021

10.1016/S0891-5520(05)70400-1

Identifiers

DOI

1 reference

6 July 2017

1 reference